不同给药方案对治疗儿童咳嗽变异性哮喘的临床效果分析
Clinical effect analysis of medication regimens on the treatment of cough variant asthma in children
娄南南 1郭晶 1马香 2盖中涛2
作者信息
- 1. 山东大学附属儿童医院呼吸科(济南 250000)
- 2. 山东大学附属儿童医院呼吸科(济南 250000);济南市儿童医院呼吸病重点实验室(济南 250000)
- 折叠
摘要
目的 探讨儿童咳嗽变异性哮喘(cough variant asthma,CVA)常见治疗方案临床疗效与最佳治疗疗程.方法 回顾性分析2019年10月至2022年6月在山东大学附属儿童医院接受治疗的CVA患儿临床资料,按照治疗方案不同分为吸入型糖皮质激素联合长效β2受体激动剂(ICS+LABA)或ICS联合白三烯受体拮抗剂(ICS+LTRA)两组,比较两组患者疾病控制情况与咳嗽症状复发率.结果 共纳入187例患者,其中ICS+LABA组50例、ICS+LTRA组137例.两种方案在CVA控制率(92.0％vs.89.8％)、咳嗽症状复发率(4.0％vs.11.7％)方面差异无统计学意义(P＞0.05).相较于ICS+LABA,ICS+LTRA方案在治疗16周时疗效最显著.结论 ICS+LABA、ICS+LTRA治疗儿童CVA疗效相当,可根据患儿年龄及患者意愿进行选择,为了达到更好的临床控制,建议至少用药16周.
Abstract
Objective To explore the clinical efficacy and the best course of treatment of cough variant asthma(CVA)in children.Methods The clinical data of children with CVA who were treated in Children's Hospital Affiliated to Shandong University from October 2019 to June 2022 were retrospectively analyzed.According to different treatment regimens,they were divided into two groups:inhaled corticosteroids combined with long-acting β2 receptor agonist(ICS+LABA)or ICS combined with leukotriene receptor antagonist(ICS+LTRA).The disease control and cough symptom recurrence rate were compared between the two groups.Results A total of 187 patients were included,with 50 in ICS+LABA group and 137 in ICS+LTRA group.There was no significant difference in CVA control rate(92.0％vs.89.8％)and cough recurrence rate(4.0％vs.11.7％)between the two regimens(P＞0.05).Compared with ICS+LABA,ICS+LTRA regimen had the most significant effect at the 16th week of treatment.Conclusion The efficacy of ICS+LABA and ICS+LTRA in the treatment of CVA in children is equivalent.It can be selected according to the age of the children and the wishes of the patients.In order to achieve better clinical control,a minimum of 16 weeks of medication is recommended.
关键词
儿童/哮喘/咳嗽变异性哮喘/ICS+LABA/ICS+LTRAKey words
Child/Asthma/Cough variant asthma/ICS+LABA/ICS+LTRA引用本文复制引用
基金项目
济南市临床科技创新项目(202225022)
出版年
2024
NETL
NSTL
万方数据